SCHEMBL20550985

SCHEMBL20550985

COc1ccc(Nc2cc(-c3ccccc3)nc(Cl)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.58
TP53 P04637 5/20 0.58
ACP1 P24666 5/20 0.55
AGPAT2 O15120 1/20 0.54
LMNA P02545 3/20 0.53
POLB P06746 2/20 0.53
KMT2A Q03164 6/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
MEN1 O00255 5/20 0.53
RAB9A P51151 3/20 0.53
GAA P10253 2/20 0.53
KDM4E B2RXH2 2/20 0.53
ALOX5 P09917 1/20 0.53
NFKB1 P19838 1/20 0.53
RECQL P46063 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
NPC1 O15118 1/20 0.52
THRB P10828 1/20 0.51
HPGD P15428 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30857514 0.87 MAPT (0.75) MAPTTP53POLBKMT2AMEN1
SCHEMBL20550980 0.87 MAPT (0.75) MAPTTP53POLBKMT2AMEN1
SCHEMBL21765569 0.85 MEN1 (0.63) MAPTTP53AGPAT2LMNAPOLB
SCHEMBL3237409 0.83 MAPT (0.67) MAPTTP53ACP1AGPAT2LMNA
SCHEMBL21750705 0.81 MAPT (0.58) MAPTTP53AGPAT2LMNAPOLB
SCHEMBL12727986 0.81 MAPT (0.65) MAPTTP53ACP1AGPAT2LMNA
SCHEMBL3235329 0.79 MAPT (0.55) MAPTTP53AGPAT2LMNAPOLB
SCHEMBL7151679 0.79 MAPT (0.62) MAPTTP53ACP1LMNAKMT2A
SCHEMBL5481520 0.78 ESR1 (0.64) MAPTLMNAPOLBKMT2ASMN1; SMN2
SCHEMBL13413895 0.78 MAPT (0.61) MAPTTP53ACP1AGPAT2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503456-B2 Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-23 US disclosed
EP-3825310-B1 TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2025-11-12 EP disclosed
US-20240391898-A1 Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2024-11-28 US disclosed
CN-112279833-B Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders and cardiomyopathy 意大利学院科技基金会 2024-04-16 CN disclosed
US-11952366-B2 Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2024-04-09 US disclosed
CN-110799505-B Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders and cardiomyopathy 意大利学院科技基金会 2022-08-30 CN disclosed
US-20220242848-A1 Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2022-08-04 US disclosed
US-11198682-B2 Substituted pyrimidines as inhibitors for a Rho family of GTP-ases FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2021-12-14 US disclosed
US-11198682-B2 Substituted pyrimidines as inhibitors for a Rho family of GTP-ases FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2021-12-14 US disclosed
EP-3619202-B1 TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2021-06-30 EP disclosed
EP-3619202-B1 TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2021-06-30 EP disclosed
EP-3825310-A1 TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES Fondazione Istituto Italiano di Tecnologia (IT) 2021-05-26 EP disclosed
EP-3825310-A1 TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES Fondazione Istituto Italiano di Tecnologia (IT) 2021-05-26 EP disclosed
CN-112279833-A Tri-substituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders and cardiomyopathy 意大利学院科技基金会 2021-01-29 CN disclosed
EP-3619202-A1 TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES Fondazione Istituto Italiano di Tecnologia (IT) 2020-03-11 EP disclosed
US-20200062733-A1 Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2020-02-27 US disclosed
US-20200062733-A1 Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2020-02-27 US disclosed
CN-110799505-A Tri-substituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders and cardiomyopathy 意大利学院科技基金会 2020-02-14 CN disclosed
WO-2018203256-A1 TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2018-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952366-B2 Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases CDC42, RHOA, TNK2 MAPT 1329/4885TP53 2062/4885ACP1 932/4885
US-12503456-B2 Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors TNK2, CDC42, CDC42BPA MAPT 878/4885TP53 1329/4885ACP1 996/4885
US-20200062733-A1 Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies CDC42, RHOA, RHOT2 MAPT 1372/4885TP53 1479/4885ACP1 2797/4885
US-20240391898-A1 Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies CDC42, RHOA, RHOT2 MAPT 1372/4885TP53 1479/4885ACP1 2797/4885
US-11198682-B2 Substituted pyrimidines as inhibitors for a Rho family of GTP-ases CDC42, TNK2, ARHGEF1 MAPT 1109/4885TP53 942/4885ACP1 594/4885
US-20220242848-A1 Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies CDC42, RHOA, RHOT2 MAPT 1372/4885TP53 1479/4885ACP1 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.